Continuing Education Company 28th Annual Hypertension, Diabetes & Dyslipidemia Conference 2024

Comprehensive Update in Cardiometabolic Risk Management for Primary Care and Specialty Practice

Overview

The Continuing Education Company 28th Annual Hypertension, Diabetes & Dyslipidemia Conference 2024 delivers a comprehensive, evidence-based review of the three most important modifiable cardiovascular risk factors: hypertension, diabetes mellitus, and dyslipidemia.

Held from June 19–21, 2024 in Charleston, South Carolina, this conference brings together nationally recognized experts to discuss contemporary guideline updates, cardiovascular outcome trials, obesity medicine, chronic kidney disease management, lipid disorders, resistant hypertension, and modern preventive cardiology strategies.

The program is divided into three focused educational tracks:

• Day 1 – Diabetes & Cardiometabolic Disease
• Day 2 – Hypertension & Kidney Disease
• Day 3 – Dyslipidemia & Preventive Cardiology

Special emphasis is placed on translating emerging evidence into practical outpatient management strategies that improve cardiovascular and metabolic outcomes.

---

Package Includes

Format

• 3 Conference Videos
• 3 Subtitle Files (VTT)
• 1 Comprehensive PDF Syllabus

Total Size

49.1 GB

Conference Date

June 19–21, 2024

Educational Level

Intermediate to Advanced

---

Learning Objectives

Upon completion of this activity, participants should be able to:

• Apply current hypertension guidelines to clinical practice.
• Optimize treatment of type 2 diabetes using modern therapies.
• Utilize GLP-1 receptor agonists and SGLT2 inhibitors appropriately.
• Manage dyslipidemia using contemporary lipid-lowering strategies.
• Develop individualized cardiovascular risk-reduction plans.
• Recognize secondary causes of hypertension.
• Improve management of obesity and cardiometabolic disease.
• Incorporate evidence from major cardiovascular outcome trials.
• Enhance preventive cardiology approaches in high-risk populations.
• Improve long-term cardiovascular and metabolic outcomes.

---

Day 1 – Focus on Diabetes & Cardiometabolic Disease

Cardiovascular Outcomes in Type 2 Diabetes

Topics Include

• Cardiovascular Outcome Trials (CVOTs)
• Glucose-Lowering Therapies
• Reduction of Major Adverse Cardiovascular Events (MACE)
• Evidence from Randomized Controlled Trials

Faculty:
Hertzel Gerstein, MD

---

Contemporary Cardiometabolic Guidelines

Topics Include

• ADA Standards of Care
• AACE Guidelines
• AHA Recommendations
• ESC/EASD Cardiometabolic Guidelines

Faculty:
Timothy Garvey, MD

---

GLP-1 Receptor Agonists & Emerging Therapies

Topics Include

• GLP-1 Receptor Agonists
• GIP/GLP-1 Dual Agonists
• Tirzepatide
• Cardiovascular Protection
• Weight Reduction
• Vascular Outcomes

Faculty:
Hertzel Gerstein, MD

---

Obesity as a Chronic Disease

Topics Include

• Obesity Pathophysiology
• Obesity Pharmacotherapy
• Long-Term Weight Management
• Future Treatment Strategies

Faculty:
Timothy Garvey, MD

---

Interactive Diabetes Cases

Topics Include

• Complex Diabetes Management
• Obesity Cases
• Cardiometabolic Risk Reduction
• Practical Clinical Decision-Making

---

Day 2 – Focus on Hypertension

Resistant Hypertension

Topics Include

• Diagnosis
• Evaluation
• Secondary Causes
• Treatment Algorithms
• Novel Therapies

Faculty:
John Basile, MD

---

Primary Aldosteronism

Topics Include

• Screening
• Diagnostic Evaluation
• Biochemical Testing
• Treatment Options

Faculty:
William Young, MD

---

Chronic Kidney Disease (CKD)

Topics Include

• CKD Management
• Diabetic Kidney Disease
• Cardiovascular Protection
• Evidence-Based Therapies

Faculty:
Matthew Weir, MD

---

Adrenal Disorders in Hypertension

Topics Include

• Pheochromocytoma
• Adrenal Incidentalomas
• Endocrine Hypertension
• Diagnostic Strategies

Faculty:
William Young, MD

---

Mineralocorticoid Receptor Antagonists

Topics Include

• Finerenone
• Novel MR Antagonists
• Outcome Data
• Cost vs Clinical Benefit

Faculty:
Matthew Weir, MD

---

Hypertension Case Discussions

Topics Include

• Resistant Hypertension Cases
• Secondary Hypertension
• CKD Management
• Practical Treatment Approaches

---

Day 3 – Focus on Dyslipidemia

LDL-Cholesterol Management

Topics Include

• LDL-C Targets
• Intensive Lipid Lowering
• Statin Therapy
• PCSK9 Inhibitors
• Emerging Lipid Therapies

Faculty:
Pam Taub, MD

---

Lipoprotein(a)

Topics Include

• Cardiovascular Risk
• Screening Strategies
• Emerging Lp(a) Therapies
• Future Treatment Options

Faculty:
Erin Michos, MD

---

Triglycerides and HDL

Topics Include

• Hypertriglyceridemia
• Residual Cardiovascular Risk
• HDL Physiology
• Novel Therapeutic Approaches

Faculty:
Pam Taub, MD

---

Lipids in Women

Topics Include

• Female-Specific Risk Factors
• Pregnancy-Related Lipid Disorders
• Menopause and Lipid Changes
• Lifetime Cardiovascular Risk

Faculty:
Erin Michos, MD

---

Interactive Lipid Cases

Topics Include

• ASCVD Prevention
• Familial Hypercholesterolemia
• High-Risk Patients
• Practical Lipid Management

---

Additional Core Topics

Cardiovascular Risk Reduction

Topics Include

• ASCVD Prevention
• Risk Stratification
• Lifestyle Intervention
• Long-Term Risk Management

---

Obesity Medicine

Topics Include

• Obesity Treatment
• Cardiometabolic Benefits
• Weight-Loss Pharmacotherapy
• Future Therapies

---

Diabetes Technology & Emerging Treatments

Topics Include

• Novel Incretin Therapies
• Cardiovascular Benefits
• Renal Protection
• Integrated Diabetes Care

---

Preventive Cardiology

Topics Include

• Primary Prevention
• Secondary Prevention
• Lifestyle Medicine
• Risk Assessment Tools

---

Educational Highlights

Evidence-Based Updates

Comprehensive review of major clinical trials and contemporary guidelines.

Practical Clinical Focus

Designed to provide immediately applicable strategies for outpatient care.

Multidisciplinary Approach

Integrates perspectives from cardiology, endocrinology, nephrology, lipidology, and primary care.

Case-Based Learning

Real-world clinical scenarios reinforce guideline implementation.

---

Target Audience

Physicians

• Cardiologists
• Endocrinologists
• Internal Medicine Physicians
• Family Medicine Physicians
• Primary Care Physicians
• Lipidologists
• Hypertension Specialists
• Geriatricians

Advanced Practice Providers

• Nurse Practitioners
• Physician Assistants

Allied Health Professionals

• Clinical Pharmacists
• Diabetes Educators
• Nurses
• Preventive Cardiology Professionals

---

Why This Course Stands Out

✔ Comprehensive review of hypertension, diabetes, and dyslipidemia

✔ Dedicated focus on cardiometabolic risk reduction

✔ Extensive coverage of GLP-1 and SGLT2 therapies

✔ Current hypertension and lipid guidelines

✔ Strong preventive cardiology emphasis

✔ Expert faculty from endocrinology, nephrology, and cardiology

✔ Practical case-based learning

✔ Direct clinical applicability